ASCO Insight: Merck’s Keytruda and Novartis’ Kisqali Face Their Moment of Truth in Early Stage Cancers – FiercePharma

Leave a Comment / Business / By
  1. ASCO preview: Merck’s Keytruda and Novartis’ Kisqali face their moment of truth in early-stage cancersFiercePharma
  2. Pfizer showcases scientific advancements of its cutting-edge oncology portfolio at the 2023 ASCO Annual MeetingPfizer
  3. Daiichi Sankyo presents the latest research aimed at creating new standards of care for cancer patients with data at ASCO and EHAbusiness thread
  4. The biggest meeting on cancer is back in full swing: ASCO 2023Medscape
  5. Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023business thread

Leave a Comment

Your email address will not be published. Required fields are marked *